Peihua Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Peihua Shi has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Jiying Wang
Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
10 shared publicationsPutao Yuan
Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
10 shared publications- Xuewu Sun
Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
9 shared publications Huali Ye
Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
8 shared publicationsBoya Zhang
Key Lab Biotherapy Zhejiang Prov, Hangzhou, Peoples R China
7 shared publicationsHai Huang
Key Laboratory of Musculoskeletal System Degeneration and Regeneration Translational Research of Zhejiang Province, Hangzhou, China
6 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 8, 0784
Visomitin Attenuates Pathological Bone Loss by Reprogramming Osteoclast Metabolism via the STAT3/LDHB Axis
A persistently substantial energy demand and metabolic reprogramming endure throughout the entire course of osteoclastogenesis, accompanied by an intensified oxidative stress. Hence, balancing cellular energy metabolism and maintaining redox homeostasis offer potential for coordinating osteoclastogenesis and bone loss in pathological conditions. In the present study, we have discovered Visomitin, a novel antioxidant that specifically targets mitochondria, which efficiently decreases intracellular reactive oxygen species (ROS) levels, inhibits osteoclastogenesis, and impairs the function of bone resorption. Mechanistically, Visomitin directly targets signal transducer and activator of transcription 3 (STAT3), leading to the inhibition of its transcriptional activity and modulation of lactate dehydrogenase B (LDHB) expression levels, consequently triggering metabolic reprogramming and exerting antagonistic effects on osteoclasts. Furthermore, administration of Visomitin demonstrates marked protective effects against pathological bone loss in vivo. Given its established clinical safety profile in ophthalmologic applications, Visomitin emerges as a promising anti-resorptive agent for clinical translation. This study also unveils the STAT3/LDHB axis as a critical nexus linking mitochondrial redox regulation to osteoclast metabolism, providing a novel therapeutic strategy for osteoclast-driven bone diseases.
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 8, 0784
Open AccessVisomitin Attenuates Pathological Bone Loss by Reprogramming Osteoclast Metabolism via the STAT3/LDHB Axis
A persistently substantial energy demand and metabolic reprogramming endure throughout the entire course of osteoclastogenesis, accompanied by an intensified oxidative stress. Hence, balancing cellular energy metabolism and maintaining redox homeostasis offer potential for coordinating osteoclastogenesis and bone loss in pathological conditions. In the present study, we have discovered Visomitin, a novel antioxidant that specifically targets mitochondria, which efficiently decreases intracellular reactive oxygen species (ROS) levels, inhibits osteoclastogenesis, and impairs the function of bone resorption. Mechanistically, Visomitin directly targets signal transducer and activator of transcription 3 (STAT3), leading to the inhibition of its transcriptional activity and modulation of lactate dehydrogenase B (LDHB) expression levels, consequently triggering metabolic reprogramming and exerting antagonistic effects on osteoclasts. Furthermore, administration of Visomitin demonstrates marked protective effects against pathological bone loss in vivo. Given its established clinical safety profile in ophthalmologic applications, Visomitin emerges as a promising anti-resorptive agent for clinical translation. This study also unveils the STAT3/LDHB axis as a critical nexus linking mitochondrial redox regulation to osteoclast metabolism, providing a novel therapeutic strategy for osteoclast-driven bone diseases.
- 2 October 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 734, 150786
Irg1 regulates bone homeostasis via regulating the Grk5 expression
- 2 October 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 734, 150786
Irg1 regulates bone homeostasis via regulating the Grk5 expression
- Open Access
- 9 July 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1
Publisher Correction: Restrained Mitf-associated autophagy by Mulberroside A ameliorates osteoclastogenesis and counteracts OVX-Induced osteoporosis in mice
- 9 July 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1
Open AccessPublisher Correction: Restrained Mitf-associated autophagy by Mulberroside A ameliorates osteoclastogenesis and counteracts OVX-Induced osteoporosis in mice
- Open Access
- 20 June 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (11) , 5008-5025
Combination of anti-inflammatory therapy and RNA interference by light-inducible hybrid nanomedicine for osteoarthritis treatment
- 20 June 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (11) , 5008-5025
Open AccessCombination of anti-inflammatory therapy and RNA interference by light-inducible hybrid nanomedicine for osteoarthritis treatment
- 4 April 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 710, 149885
Disease-modifying potential of diphenyl diselenide in an experimental osteoarthritis model
- 4 April 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 710, 149885
Disease-modifying potential of diphenyl diselenide in an experimental osteoarthritis model
- Open Access
- 28 February 2024
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 15 (7) , 3552-3565
Urolithin B reduces cartilage degeneration and alleviates osteoarthritis by inhibiting inflammation
Urolithin B, generated through the metabolism of microbiota, exhibits anti-inflammatory and cartilage-protective effects.
- 28 February 2024
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 15 (7) , 3552-3565
Open AccessUrolithin B reduces cartilage degeneration and alleviates osteoarthritis by inhibiting inflammation
Urolithin B, generated through the metabolism of microbiota, exhibits anti-inflammatory and cartilage-protective effects.
- Open Access
- 15 February 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-15
Restrained Mitf-associated autophagy by Mulberroside A ameliorates osteoclastogenesis and counteracts OVX-Induced osteoporosis in mice
Bone and mineral metabolism homeostasis accounts for the maintenance of normal skeletal remodeling. However, with aging and changes in hormone levels, over-activated osteoclasts disrupt homeostasis, induce osteoporosis, and even cause osteoporotic fractures, leading to an enormous economic burden. Despite the rapid development of pharmacological therapy for osteoporosis, safer and more effective treatments remain to be explored. Here, we demonstrate that Mulberroside A (Mul-A), a natural component extracted from mulberry bark and branches, effectively suppresses osteoclastogenesis in vitro and counteracts bone loss caused by ovariectomy (OVX). The mechanism underlying this effect involves the repression of autophagic flux during osteoclastogenesis by Mul-A, which can be attributed to the restrained expression of microphthalmia-related transcription factor (Mitf) and its nuclear translocation. Importantly, Mitf overexpression partially reverses the inhibitory effects of Mul-A on autophagy and osteoclastogenesis. Moreover, applying two autophagy agonizts, rapamycin and Torin 1, attenuates the osteoclastogenic regulatory role of Mul-A. Collectively, our study demonstrates that Mul-A damages osteoclast differentiation and ameliorates osteoporosis caused by estrogen deficiency by modulation of Mitf-associated autophagy, indicating its therapeutic potential against osteoporosis.
- 15 February 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-15
Open AccessRestrained Mitf-associated autophagy by Mulberroside A ameliorates osteoclastogenesis and counteracts OVX-Induced osteoporosis in mice
Bone and mineral metabolism homeostasis accounts for the maintenance of normal skeletal remodeling. However, with aging and changes in hormone levels, over-activated osteoclasts disrupt homeostasis, induce osteoporosis, and even cause osteoporotic fractures, leading to an enormous economic burden. Despite the rapid development of pharmacological therapy for osteoporosis, safer and more effective treatments remain to be explored. Here, we demonstrate that Mulberroside A (Mul-A), a natural component extracted from mulberry bark and branches, effectively suppresses osteoclastogenesis in vitro and counteracts bone loss caused by ovariectomy (OVX). The mechanism underlying this effect involves the repression of autophagic flux during osteoclastogenesis by Mul-A, which can be attributed to the restrained expression of microphthalmia-related transcription factor (Mitf) and its nuclear translocation. Importantly, Mitf overexpression partially reverses the inhibitory effects of Mul-A on autophagy and osteoclastogenesis. Moreover, applying two autophagy agonizts, rapamycin and Torin 1, attenuates the osteoclastogenic regulatory role of Mul-A. Collectively, our study demonstrates that Mul-A damages osteoclast differentiation and ameliorates osteoporosis caused by estrogen deficiency by modulation of Mitf-associated autophagy, indicating its therapeutic potential against osteoporosis.
- Open Access
- 11 May 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1
Author Correction: CircFNDC3B regulates osteoarthritis and oxidative stress by targeting miR-525-5p/HO-1 axis
- 11 May 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1
Open AccessAuthor Correction: CircFNDC3B regulates osteoarthritis and oxidative stress by targeting miR-525-5p/HO-1 axis
- Open Access
- 27 February 2023
- Published by Wiley
Restrained Mitf-associated autophagy by Mulberroside A ameliorates osteoclastogenesis and counteracts OVX-Induced osteoporosis in mice
Background and Purpose: Overactivated osteoclasts disrupt the mineral homeostasis of bone, inducing osteoporosis. Despite the rapid development of pharmacological therapy in osteoporosis, a safer and more effective treatment remains to be explored. Recently, the connection between osteoporosis and autophagy has gained more attention. Autophagy activation promotes osteoclastogenesis and the development of osteoporosis. Mulberroside A (Mul-A), a natural component extracted from mulberry bark and branches, has various pharmacological functions. Nevertheless, the role of Mulberroside A on osteoporosis and autophagy is unknown. Here, we aimed to investigate the changes in osteoclastogenesis and autophagy occurrence in response to Mulberroside A. Experimental and Approach: TRAP staining and bone resorption assay were used to confirm the inhibitory effect of Mul-A on osteoclastogenesis and function. Western blot, Quantitative real-time PCR, transmission electron microscope and confocal microscope were performed to explore the mechanism. Ovariectomy(OVX) was employed to verify the therapeutic effect of Mul-A on osteoporosis in vivo. Key Results: Mul-A effectively suppresses osteoclastogenesis in vitro and counteracts the bone loss caused by ovariectomy(OVX). Mechanically, Mul-A represses the occurrence of autophagy flux during osteoclastogenesis, which can be attributed to the restrained expression of microphthalmia-related transcription factor(Mitf) and its nuclear translocation. Moreover, the application of two autophagy agonists, rapamycin and Torin 1, attenuates the osteoclastogenic regulatory role of Mul-A as well. Conclusions and Implications: Our study demonstrates that Mul-A damages the differentiation of osteoclasts and ameliorates osteoporosis caused by estrogen deficiency through modulation of Mitf-associated autophagy, suggesting its therapeutic potential against osteoporosis.
- 27 February 2023
- Published by Wiley
Open AccessRestrained Mitf-associated autophagy by Mulberroside A ameliorates osteoclastogenesis and counteracts OVX-Induced osteoporosis in mice
Background and Purpose: Overactivated osteoclasts disrupt the mineral homeostasis of bone, inducing osteoporosis. Despite the rapid development of pharmacological therapy in osteoporosis, a safer and more effective treatment remains to be explored. Recently, the connection between osteoporosis and autophagy has gained more attention. Autophagy activation promotes osteoclastogenesis and the development of osteoporosis. Mulberroside A (Mul-A), a natural component extracted from mulberry bark and branches, has various pharmacological functions. Nevertheless, the role of Mulberroside A on osteoporosis and autophagy is unknown. Here, we aimed to investigate the changes in osteoclastogenesis and autophagy occurrence in response to Mulberroside A. Experimental and Approach: TRAP staining and bone resorption assay were used to confirm the inhibitory effect of Mul-A on osteoclastogenesis and function. Western blot, Quantitative real-time PCR, transmission electron microscope and confocal microscope were performed to explore the mechanism. Ovariectomy(OVX) was employed to verify the therapeutic effect of Mul-A on osteoporosis in vivo. Key Results: Mul-A effectively suppresses osteoclastogenesis in vitro and counteracts the bone loss caused by ovariectomy(OVX). Mechanically, Mul-A represses the occurrence of autophagy flux during osteoclastogenesis, which can be attributed to the restrained expression of microphthalmia-related transcription factor(Mitf) and its nuclear translocation. Moreover, the application of two autophagy agonists, rapamycin and Torin 1, attenuates the osteoclastogenic regulatory role of Mul-A as well. Conclusions and Implications: Our study demonstrates that Mul-A damages the differentiation of osteoclasts and ameliorates osteoporosis caused by estrogen deficiency through modulation of Mitf-associated autophagy, suggesting its therapeutic potential against osteoporosis.
- Open Access
- 20 February 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-15
CircFNDC3B regulates osteoarthritis and oxidative stress by targeting miR-525-5p/HO-1 axis
Osteoarthritis (OA) is a common chronic degenerative joint disease associated with a variety of risk factors including aging, genetics, obesity, and mechanical disturbance. This study aimed to elucidate the function of a newly discovered circular RNA (circRNA), circFNDC3B, in OA progression and its relationship with the NF-κB signaling pathway and oxidative stress. The circFNDC3B/miR-525-5p/HO-1 axis and its relationship with the NF-κB signaling pathway and oxidative stress were investigated and validated using fluorescence in situ hybridization, real-time PCR, western blotting, immunofluorescence analysis, luciferase reporter assays, pull-down assays, and reactive oxygen species analyses. The functions of circFNDC3B in OA was investigated in vitro and in vivo. These evaluations demonstrated that circFNDC3B promotes chondrocyte proliferation and protects the extracellular matrix (ECM) from degradation. We also revealed that circFNDC3B defends against oxidative stress in OA by regulating the circFNDC3B/miR-525-5p/HO-1 axis and the NF-κB signaling pathway. Further, we found that overexpression of circFNDC3B alleviated OA in a rabbit model. In summary, we identified a new circFNDC3B/miR-525-5p/HO-1 signaling pathway that may act to relieve OA by alleviating oxidative stress and regulating the NF-κB pathway, resulting in the protection of the ECM in human chondrocytes, highlighting it as a potential therapeutic target for the treatment of OA.
- 20 February 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-15
Open AccessCircFNDC3B regulates osteoarthritis and oxidative stress by targeting miR-525-5p/HO-1 axis
Osteoarthritis (OA) is a common chronic degenerative joint disease associated with a variety of risk factors including aging, genetics, obesity, and mechanical disturbance. This study aimed to elucidate the function of a newly discovered circular RNA (circRNA), circFNDC3B, in OA progression and its relationship with the NF-κB signaling pathway and oxidative stress. The circFNDC3B/miR-525-5p/HO-1 axis and its relationship with the NF-κB signaling pathway and oxidative stress were investigated and validated using fluorescence in situ hybridization, real-time PCR, western blotting, immunofluorescence analysis, luciferase reporter assays, pull-down assays, and reactive oxygen species analyses. The functions of circFNDC3B in OA was investigated in vitro and in vivo. These evaluations demonstrated that circFNDC3B promotes chondrocyte proliferation and protects the extracellular matrix (ECM) from degradation. We also revealed that circFNDC3B defends against oxidative stress in OA by regulating the circFNDC3B/miR-525-5p/HO-1 axis and the NF-κB signaling pathway. Further, we found that overexpression of circFNDC3B alleviated OA in a rabbit model. In summary, we identified a new circFNDC3B/miR-525-5p/HO-1 signaling pathway that may act to relieve OA by alleviating oxidative stress and regulating the NF-κB pathway, resulting in the protection of the ECM in human chondrocytes, highlighting it as a potential therapeutic target for the treatment of OA.